Brain activity patterns in people with hidradenitis suppurativa and how treatments may relate to changes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses resting-state fMRI to compare brain activity between adults with hidradenitis suppurativa (HS) and healthy controls. It also examines how brain activity correlates with HS severity, pain, sleep problems, anxiety, depression, and quality of life. Participants with HS will be followed for about three months to observe brain changes after routine biologic or small-molecule therapy, and these changes will be related to symptom improvement. Healthy controls of similar age and sex are included for comparison. The study is conducted at Second Xiangya Hospital in Changsha, China, with adult HS participants and matched healthy volunteers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

For Participants With Hidradenitis Suppurativa:

* Aged 18 to 45 years.
* Diagnosed with hidradenitis suppurativa according to established clinical diagnostic criteria.
* Able and willing to comply with the study procedures and follow-up assessments.
* Able to provide written informed consent and willing to permit photography of affected skin areas.
* No coexisting systemic lupus erythematosus, dermatomyositis, atopic dermatitis, steroid-dependent dermatitis, or other relevant skin diseases.
* No use of biologic or small-molecule therapy that may affect hidradenitis suppurativa symptoms within 3 months before enrollment.
* Right-handed according to the Edinburgh Handedness Inventory.

For Healthy Participants:

* Aged 18 to 55 years.
* No hidradenitis suppurativa or other chronic skin disease.
* No chronic pain disorder.
* No major neurological or psychiatric disorder.
* Right-handed according to the Edinburgh Handedness Inventory.
* Able to provide written informed consent and comply with the study procedures.

For the Longitudinal Treatment Cohort:

* Meets the eligibility criteria for participants with hidradenitis suppurativa.
* Is scheduled to receive biologic or small-molecule therapy for hidradenitis suppurativa as part of routine clinical care, as determined by the treating physician.
* Willing and able to complete assessments before treatment and during 3 months of follow-up.

Exclusion Criteria:

* Participation in another investigational drug study within 1 month before enrollment.
* Alcohol or drug abuse or dependence within the previous 3 months.
* Current use of medications that may lower the seizure threshold or current use of antidepressant medication.
* Previous or current treatment with electroconvulsive therapy, vagus nerve stimulation, or transcranial magnetic stimulation.
* Serious cardiac, hepatic, pulmonary, renal, thyroid, hematologic, or other systemic disease; malignant tumor; or another clinically significant abnormality that, in the investigator's judgment, makes participation inappropriate.
* Pregnancy or breastfeeding.
* Schizophrenia, bipolar disorder, or another major psychiatric disorder.
* A neurological condition that may interfere with participation or interpretation of the imaging results, including markedly elevated intracranial pressure, intracranial vascular lesions, impaired consciousness, or inability to cooperate with study procedures.
* Any contraindication to magnetic resonance imaging, including intracranial metallic foreign bodies, cardiac pacemakers, incompatible vascular or cardiac implants, or claustrophobia.
* Inability to remain still or comply with resting-state functional magnetic resonance imaging procedures.
* Unwillingness to allow study data to be collected.

Where it's running

• Second Xiangya Hospital of Central South University
  Changsha, Hunan, China Recruiting

Study contacts

• Principal investigator: Yi Zhan — Second Xiangya Hospital of Central South University
• Study coordinator: Yanyang Wu
• Email: wuyanyang@csu.edu.cn
• Phone: +86-13676781917

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Soquelitinib in adults with hidradenitis suppurativa

  This study tests whether oral soquelitinib can help adults with moderate-to-severe hidradenitis suppurativa.

  Recruiting at 9 sites Phase 1 Corvus Pharmaceuticals, Inc. · West Lafayette, Indiana and 10 other locations · NCT07828860

• ORKA-002 versus placebo for moderate-to-severe hidradenitis suppurativa

  A study tests ORKA-002 against placebo in adults with moderate-to-severe hidradenitis suppurativa to see if it helps reduce symptoms.

  Recruiting at 25 sites Phase 2 Oruka Therapeutics, Inc. · Birmingham, Alabama and 24 other locations · NCT07783542

• SPY072 in adults with moderate to severe hidradenitis suppurativa

  This study tests whether SPY072 can help adults with moderate to severe hidradenitis suppurativa when added to their current care, compared with a placebo over 16 weeks.

  Recruiting at 7 sites Phase 2 Spyre Therapeutics, Inc. · Birmingham, Alabama and 33 other locations · NCT07766005

• Roflumilast 0.3% Foam for Hidradenitis Suppurativa in Teens and Adults

  This study tests a topical roflumilast foam to see if it improves HS in adolescents and adults over 16 weeks.

  Recruiting Phase 2 Harrison Dermatology · Missouri City, Texas · NCT07689188

• Global health study on hidradenitis suppurativa

  This study tests how people with hidradenitis suppurativa access care and what treatments they receive across different health systems.

  Recruiting University of Zurich · Zurich · NCT07659769

• Secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa

  This trial tests two dosing regimens of secukinumab to see if they can help Chinese adults with moderate to severe hidradenitis suppurativa.

  Recruiting at 10 sites Phase 4 Novartis · Guangzhou, Guangdong and 9 other locations · NCT07489573

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.